The 2025 International Society on Thrombosis & Hemostasis (ISTH) conference has concluded. From June 21 through June 25, the ISTH Congress saw health professionals gather from around the world for the annual event.

With so much insightful research presented at the event, we compiled a handful of posters that are related to inherited bleeding disorders, for your convenience. 

Physical Activity and Cardiovascular Health of Hemophiliac Patients: Experience of a Tertiary Center
  • Description: This study evaluated the physical activity and cardiovascular risk control in hemophiliac patients by using over 40 years of data from a tertiary center to help determine barriers to physical activity.
  • Result: The combination of a high BMI and severe hemophilia was associated with a reduced capacity for physical activity. Research yielded no statistically relevant relationships between diet and cardiovascular risk, or in interactions of hypertension, physical activity, and treatment modality.

Real-world Use of Emicizumab in Surgery: A Systematic Review

  • Description: This systematic review evaluated the outcomes of emicizumab in real-world, surgical settings.
  • Result: Researchers found that emicizumab is an effective monotherapy option in minor surgeries in 56% of procedures in patients without FVIII-inhibitors, and in 58% of patients with hemophilia A. Major bleeding occurred in 3% of patients with hemophilia A despite additional treatment.

A Phase 2 Dose-escalation Substudy of Fidanacogene Elaparvovec in Adults with Hemophilia B

  • Description: This study was conducted to evaluate dose escalation of fidanacogene elaparvovec in patients with hemophilia B.
  • Result: A solitary infusion of fidanacogene elaparvovec in patients with hemophilia B was typically well tolerated. Factor IX activity levels were higher with a higher vector dose. The activity levels fell within a normal range among both dose cohorts.

Balancing the Thrombotic and Haemorrhagic Risk of Non-severe Haemophilia A in Major Surgery

  • Description: This study described a pair of major surgeries that were at high thromboembolic risk in non-severe hemophilia A patients.
  • Result: The two cases confirmed that managing thrombotic risk in patients with hemophilia who undergo major surgery is complex and requires an approach personalized to the patient. Multidisciplinary management is key in balancing haemorrhagic and thrombotic risk.

Early Emicizumab Prophylaxis Does Not Prevent FVIII Inhibitor Occurrence in MTP with Severe HA

  • Description: This study presented real-world data of emicizumab prophylaxis and its outcomes in hemophilia A patients younger than a year old.
  • Result: The study highlighted a shift toward earlier prophylaxis in severe HA. 18% of minimally treated patients with high-risk mutations developed FVIII inhibitors after 5-12 exposure days to FVIII. 

The Impact of Severe Nutritional Vitamin K Deficiency on Emicizumab Therapy

  • Description: Researchers focused on how a vitamin K deficiency can impair emicizumab efficacy in a patient with hemophilia A and unexpected bleeding.
  • Result: The case highlights the need for nutritional considerations, particularly in cognitively impaired patients, when managing unexpected bleeding.

For a look at the complete rundown of events, visit the official ISTH 2025 website.

Sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, all rights reserved.